PORCOMPLEX™ (FRANÇAIS)
DESCRIPTION
La Précommande Institutionnelle Prioritaire PORCOMPLEX™ permet aux institutions, groupes hospitaliers, laboratoires, centres de recherche, fonds d'investissement, gouvernements et organisations partenaires de bénéficier d'un crédit institutionnel d'une contre-valeur de 50 000 000 USD.
Cette contre-valeur est destinée à l'acquisition future de produits, services, programmes de recherche et solutions biomédicales proposés dans le catalogue professionnel PORCOMPLEX™.
AVANTAGES
✓ Accès prioritaire au catalogue professionnel PORCOMPLEX™
✓ Conditions "Wholesale" réservées aux partenaires institutionnels
✓ Réservation anticipée des capacités de production futures
✓ Priorité sur les programmes pilotes et démonstrateurs
✓ Crédit sans date d'expiration
✓ Utilisation fractionnée ou globale
✓ Transférable sous réserve d'approbation PORCOMPLEX™
MODALITES
Montant : 50 000 000 USD
Sécurisation : ESCROW.COM
Validité : Illimitée
Utilisation : Produits et services PORCOMPLEX™ éligibles
Bénéficiaire : Institution, société, laboratoire ou organisme agréé
AVERTISSEMENT
La présente précommande constitue un droit d'accès prioritaire au catalogue PORCOMPLEX™ et ne constitue ni une action, ni une obligation, ni un produit financier réglementé.
CONTACT
CONTACT@PORCOMPLEX.NET
THERA.PORCOMPLEX.COM
PORCOMPLEX
PORCOMPLEX™ is a biotechnology and clinical research initiative dedicated to developing medical applications using genetically modified (GMO) pigs. Developed and coordinated by MASSOURCING CORPORATION, the project aims to address global shortages of organs, tissues, and blood products by providing clinically certified porcine resources compatible with human and veterinary medicine.
# Core Mission and Standards
The primary mission of PORCOMPLEX™ is to create innovative biomedical solutions for patients suffering from end-stage organ failure and traumatic injuries. Unlike conventional livestock, these animals are not intended for food production; they are raised under strict clinical-grade standards, including:
* Genetic monitoring and biosecurity protocols.
* Permanent veterinary supervision and clinical traceability.
* Compliance with ethical oversight and research standards.
# Key Research and Clinical Programs
The initiative focuses on a wide range of regenerative and transplant-related fields:
* Xenotransplantation: Development of porcine organs—including the heart, kidneys, liver, lungs, and pancreas—intended for human transplantation.
* Tissue Reconstruction: Clinical-grade tissues for severe burn treatment, wound management, and advanced skin reconstruction.
* Aesthetic & Reconstructive Medicine:
* Biological Breast Reconstruction: A biological alternative to silicone implants using bioengineered porcine tissues.
* Hair & Facial Hair Restoration: Long-term biological solutions for baldness and facial hair reconstruction through follicular grafting.
* Body Remodeling: Using porcine-derived biological tissues as alternatives to synthetic fillers.
* Advanced Therapies:
* PORCOS EXTENSION LIFE™: Research into extending healthy human lifespan through aging organ replacement and neurological repair.
* Porcine Rejuvenation Therapy™: Cellular anti-aging treatments and wrinkle reduction.
* Blood Regeneration: Addressing shortages by developing porcine-derived blood components.
# Infrastructure and Global Presence
PORCOMPLEX™ operates through private clinics, research laboratories, and certified farms. A significant upcoming development is the PORCOMPLEX Comoros Project, which aims to establish the first transgenic pig laboratory farm in the Comoros Islands, featuring secure breeding facilities and international scientific partnerships.
# Regulatory Status
It is important to note that the technologies described are currently in research, experimental, and prospective stages. Their availability for clinical use is strictly subject to scientific validation, clinical trials, and regulatory approval within applicable jurisdictions.
Name a fair price:
What You'll Get:
- CONTRE-VALEUR
- 50 000 000 USD
- Accès Prioritaire à l'Innovation Biomédicale Porcine